*ST生物保壳自救“连环招”

Core Viewpoint - *ST Bio is undertaking a new round of restructuring efforts to avoid delisting risks by planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. through cash payment, aiming to enhance its profitability and operational efficiency [1][4][10]. Group 1: Acquisition Details - On August 12, *ST Bio announced the signing of a share acquisition intention agreement to acquire 51% of Huize Biomedical, a company specializing in drug research and clinical evaluation, with over 85% of its revenue coming from clinical evaluation services [4][10]. - The acquisition is intended to extend *ST Bio's biopharmaceutical business and improve its main business profitability, while also enhancing operational efficiency through asset integration [4][10]. Group 2: Stock Performance - Prior to the restructuring announcement, *ST Bio's stock experienced two consecutive days of trading at the upper limit, with a peak price of 12.54 yuan per share on August 11, marking a new high for the year and a trading volume of 1.07 billion yuan [5][6]. - Following the announcement, *ST Bio's stock hit the lower limit on August 12, closing at 11.91 yuan per share, reflecting a decline of 5.02% [6]. Group 3: Financial Status and Risks - *ST Bio has been under delisting risk warning since April 30, 2023, due to negative financial performance, including a projected revenue of approximately 1.34 billion yuan and a net loss of about 19.85 million yuan for 2024 [8][9]. - The company has taken multiple self-rescue measures, including selling loss-making subsidiaries and restructuring its board of directors to improve its financial situation and operational capabilities [10][11].